Inhibrx Biosciences (INBX) Long-Term Debt Issuances (2025)
Inhibrx Biosciences (INBX) posted quarterly Long-Term Debt Issuances of $100.0 million for Q1 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Long-Term Debt Issuances (2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Long-Term Debt Issuances for 1 consecutive years, with $100.0 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Long-Term Debt Issuances changed N/A year-over-year to $100.0 million; the TTM figure through Dec 2025 stood at $100.0 million (changed N/A YoY), while the FY2025 annual figure was $100.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances held at $100.0 million in Q1 2025 per INBX's latest filing.
- Across five years, Long-Term Debt Issuances topped out at $100.0 million in Q1 2025 and bottomed at $100.0 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |